Bonetta Volume HA Filler
High-density crosslinked hyaluronic acid dermal filler with SmartCross™ Technology (G’ value: 380Pa) demonstrating 92% persistence at 12 months
Advanced Crosslinking & Rheological Properties
Bonetta Volume employs patented NASHA® filtration system with 6.2% crosslinking ratio, achieving optimal viscoelasticity (Storage Modulus: 380Pa, Loss Modulus: 68Pa). The 45μm particulate size distribution ensures smooth tissue integration while maintaining 24mg/mL HA concentration. Clinical studies demonstrate 89% reduction in edema incidence compared to conventional fillers.
Key Clinical Advantages
Longevity
12-18 month duration with 92% HA retention at 12 months (n=150)
Smooth Injection
58% lower extrusion force (0.21N) vs market average
Pain Management
0.3% lidocaine reduces VAS pain scores by 74%
Rapid Recovery
83% patients resume normal activity within 24hrs
Product Specifications
- Composition: 24mg/mL HA · 0.3% Lidocaine HCl
- Crosslinking: 6.2% BDDE · 45μm particle size
- Packaging: 2×1.1ml sterile Luer-Lok® syringes
- pH: 7.2±0.3 · Osmolarity: 290mOsm/kg
- Storage: 25°C · Avoid freezing
- Shelf Life: 24 months unopened
Injection Protocol
- Needle: 27G ½” · 30G for lips
- Depth: Mid-deep dermis (2.5-4mm)
- Technique: Linear threading · Fanning
- Max Volume: 2.2ml per session
- Anesthesia: Not required (pre-incorporated)
Aesthetic Indications
Facial Volumization
Cheek augmentation: 0.8-1.2ml per side using blunt cannula. Maintain supraperiosteal placement for natural projection.
Lip Enhancement
Vertical injection technique: 0.3-0.5ml per lip quadrant. Achieve 1.2-1.5mm projection increase per session.
Rhytid Correction
Nasolabial folds: 0.4-0.6ml per fold using retrograde linear technique. 89% patient satisfaction at 6 months.
Clinical Advisory
Important: Individual results may vary based on tissue characteristics and injection technique. Use only by licensed practitioners with aesthetic medicine certification. Contraindicated in pregnancy, active skin infections, or hypersensitivity to lidocaine.
Post-treatment monitoring required for 30 minutes. Avoid NSAIDs 48hrs pre-treatment. Report any vascular compromise immediately.
Reviews
There are no reviews yet.